Grant M. Gallagher

A Rapid Response in BMJ argues that to achieve Zero-COVID, we need to broaden our thinking to include the controlled and careful acquisition of population immunity.

In this segment, Dysphagia expert Rinki Varindani Desai shares her perspective on the need for an adaptive health care system response that incorporates equity across health burdens.

A total of 9 firms signed the letter promising to put safety at the top of the priority list in ongoing COVID-19 vaccine development projects.

Rising costs from 2014-2018 may have hindered PrEP expansion, according to a recent retrospective study.

A follow-up on analysis from earlier in the pandemic reveals that virulence in children remained stable over a 5-month period.

The following is a quick review of the week’s top FDA approvals and authorizations.

A review of the week's top infectious disease news, including links established between mental health and pursuit of need medical care during COVID-19.

New study suggests a connection between widespread mental health challenges and the decline in care during COVID-19.

Rinki Varindani Desai shares some of the challenges COVID-19 patients with lung injury have faced with Medicare after leaving the hospital.

Dysphagia specialist Rinki Varindani Desai shares her perspective on how COVID-19 has impacted her work and patients.

A trio of studies appearing in JAMA today now support steroid use to reduce mortality in patients with severe SARS-CoV-2 infections.

Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.

One effort to develop a SARS-CoV-2 vaccine focuses on combining antibody and T cell immunity, using a gp96 protein based technology.

The Roche test supports rapid molecular detection of acute HIV infection, with differentiation between HIV-1 and -2.

A new CDC Morbidity and Mortality Weekly Report adds information on seroprevalence of SARS-CoV-2 among health care workers in a 13-hospital multistate medical network between April and June of 2020.

A study team examined asthma prevalence in patients hospitalized for COVID-19 with population asthma prevalence and a 4-year average of asthma prevalence in influenza hospitalizations across the United States.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at USP, discusses the recent report of SARS-CoV-2 reinfection.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the fundamentals of convalescent plasma treatment for COVID-19.

Bhopal’s recent article, COVID-19 Zugzwang, was published in Public Health in Practice.

The FDA regularly posts updates on recalls, outbreak investigations, and related regulatory activities. Weekly, we identify which of those announcements might be most clinically relevant.

John F. Kokai-Kun, PhD, explains the supply chain and logistical issues limiting the scale of monoclonal antibody treatment.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the fundamentals of monoclonal antibody treatment.

Hospital admissions for stroke fell by nearly a third during March and April 2020 alone when compared with those months in 2019.

A study team assessed 4 methods of N95 mask decontamination, with results suggesting that proper procedure can allow the reuse of masks 2-3 times.

Martin Kulldorff, PhD, explains that masks can't replace social distancing for those at highest risk for severe COVID-19.

Martin Kulldorff, PhD, answers whether an age based coronavirus strategy would worsen the pandemic's impact on workers and minority racial groups.

Soon after visiting 38 hospitals in Michigan, over half of patients hospitalized with suspected COVID-19 received antibiotics.

The US Centers for Disease Control and Prevention has updated COVID-19 guidance, sharing advice on safe travel

John Johnson, lead for Ebola vaccination with MSF France, describes the "ring strategy" used in controlling several infectious disease threats.

Martin Kulldorff, PhD, takes a total social health perspective on the global use of mass quarantines as a primary COVID-19 control strategy.